Abstract P3-10-09: Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (Pembro)+chemotherapy (Chemo) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial | Citedby Results | Cancer Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Abstract P3-10-09: Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (Pembro)+chemotherapy (Chemo) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial

Cancer Res (2019) 79 (4_Supplement): P3-10-09.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Immunotherapy in triple-negative breast cancer: A literature review and new advances

Guillermo Arturo Valencia
Patricia Rioja
Zaida Morante
Rossana Ruiz
Hugo Fuentes
Carlos A Castaneda
Tatiana Vidaurre
Silvia Neciosup
Henry L Gomez

World Journal of Clinical Oncology (2022) 13 (3): 219.

Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence

Melina Farshbafnadi
Amin Pastaki Khoshbin
Nima Rezaei

International Immunopharmacology (2021) 98: 107876.

The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice

The Journal of Pathology (2020) 250 (5): 667.

Recent advances in triple negative breast cancer: the immunotherapy era

Antonio Marra
Giulia Viale
Giuseppe Curigliano

BMC Medicine (2019) 17 (1)